Literature DB >> 15063571

Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant.

Seema Iyer1, R S Robin Robinett, Harm HogenEsch, Stanley L Hem.   

Abstract

Hepatitis B surface antigen (HBsAg) differs from many antigens because of its associated lipid bilayer that is largely composed of phospholipids. In general, phosphate groups adsorb strongly to hydroxylated mineral surfaces by ligand exchange. The purpose of this study was to investigate the mechanism of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant with emphasis on the role of phospholipids in this adsorption. The adsorption of HBsAg by aluminum hydroxide adjuvant exhibits a high affinity adsorption isotherm. The Langmuir equation was used to calculate the adsorptive capacity (1.7 microg/microg Al), which is the amount of HBsAg adsorbed at monolayer coverage and the adsorptive coefficient (6.0 ml/microg), which is a measure of the strength of the adsorption force. The relatively high value of the adsorptive coefficient indicates that adsorption is due to a strong attractive force. Ligand exchange between a phosphate of the antigen and a surface hydroxyl of the adjuvant provides the strongest adsorption mechanism. The adsorption capacity of HBsAg was not affected by increased ionic strength indicating that electrostatic attraction is not the predominant adsorption force. Adsorption was also not affected by the addition of ethylene glycol indicating that hydrophobic interactions were not the predominant adsorption force. The strength of the adsorption force was indicated by the resistance of HBsAg to elution when exposed to interstitial fluid. Less than 5% of the HBsAg adsorbed to aluminum hydroxide adjuvant in a model vaccine was eluted during a 12 h in vitro exposure to interstitial fluid at 37 degrees C. Less than 1% of the adsorbed HBsAg in two commercial vaccines was eluted by in vitro exposure to interstitial fluid for 48 h at 37 degrees C. Thus, it was concluded that adsorption of HBsAg by aluminum hydroxide adjuvant is predominantly due to ligand exchange between the phospholipids in HBsAg and surface hydroxyls in aluminum hydroxide adjuvant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063571     DOI: 10.1016/j.vaccine.2003.10.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.

Authors:  Yue Zhang; Min Li; Fan Yang; Yufang Li; Zizheng Zheng; Xiao Zhang; Qingshan Lin; Ying Wang; Shaowei Li; Ningshao Xia; Jun Zhang; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

3.  Engineering the hydroxyl content on aluminum oxyhydroxide nanorod for elucidating the antigen adsorption behavior.

Authors:  Ge Yu; Zhihui Liang; Zilan Yu; Min Li; Wenqi Yang; Yawei Zhang; Yuhang Zhao; Cheng Yang; Changying Xue; Li Shi; Bingbing Sun
Journal:  NPJ Vaccines       Date:  2022-06-23       Impact factor: 9.399

Review 4.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

Review 5.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

6.  Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer.

Authors:  Daming Zhu; Shuhui Huang; Holly McClellan; Weili Dai; Najam R Syed; Elizabeth Gebregeorgis; Kelly M Rausch; Gregory E D Mullen; Carole Long; Laura B Martin; David Narum; Patrick Duffy; Louis H Miller; Allan Saul
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

7.  Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine.

Authors:  Paul E Makidon; Anna U Bielinska; Shraddha S Nigavekar; Katarzyna W Janczak; Jessica Knowlton; Alison J Scott; Nicholas Mank; Zhengyi Cao; Sivaprakash Rathinavelu; Michael R Beer; J Erby Wilkinson; Luz P Blanco; Jeffrey J Landers; James R Baker
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

8.  Patterns of binding of aluminum-containing adjuvants to Haemophilus influenzae type b and meningococcal group C conjugate vaccines and components.

Authors:  Robert B D Otto; Karena Burkin; Saba Erum Amir; Dennis T Crane; Barbara Bolgiano
Journal:  Biologicals       Date:  2015-07-17       Impact factor: 1.856

9.  Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Authors:  Christopher B Fox; Mark T Orr; Neal Van Hoeven; Sarah C Parker; Traci J T Mikasa; Tony Phan; Elyse A Beebe; Ghislain I Nana; Sharvari W Joshi; Mark A Tomai; James Elvecrog; Timothy R Fouts; Steven G Reed
Journal:  J Control Release       Date:  2016-11-12       Impact factor: 9.776

10.  From Stock Bottle to Vaccine: Elucidating the Particle Size Distributions of Aluminum Adjuvants Using Dynamic Light Scattering.

Authors:  Emma Shardlow; Matthew Mold; Christopher Exley
Journal:  Front Chem       Date:  2017-01-09       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.